(A) One-year overall survival (OS) rate was 100%, 83.5±6.9%, 56.1±12.8% in favorable, intermediate, and adverse risk group, respectively. (B) One-year leukemia-free survival (LFS) rate was 91.7±5.6%, 77.0±6.8%, and 43.8±12.8% in favorable, intermediate, and adverse risk group, respectively. In patients with intermediate risk NPM1^wt/FLT3-ITD^neg/low, (C) one-year OS rate was 87.9±5.8%, and (D) one-year LFS rate was 75.6±7.7%, which were comparable to favorable risk group.